Clinical trial
FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial…
NCT00137540 · Biosense Webster EMEA, Industry · Completed
Key facts
| NCT number | NCT00137540 |
|---|---|
| Title | FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT) |
| Official title | First Line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment |
| Lead sponsor | Biosense Webster EMEA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Device, Drug |
| Interventions | RF ablation, anti-arrhythmic drug therapy |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Aug 30, 2005 |
| Last update posted | Feb 3, 2025 |
At a glance
- No Results posted
- 10–99 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: